Cargando…

Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure

Background. Presenting numeric data alone may result in patients underappreciating clinically significant benefits. Contextualizing statements to counter this may raise concern about absence of neutrality. These issues arose during construction of a decision aid for sacubitril-valsartan, a heart fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomson, Mary C., Allen, Larry A., Halpern, Scott D., Ko, Yi-An, Matlock, Daniel D., Mitchell, Andrea R., Moore, Miranda A., Morris, Alanna A., Rao, Birju R., Scherer, Laura D., Speight, Candace D., Ubel, Peter A., Dickert, Neal W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529322/
https://www.ncbi.nlm.nih.gov/pubmed/34693019
http://dx.doi.org/10.1177/23814683211041623
_version_ 1784586447176597504
author Thomson, Mary C.
Allen, Larry A.
Halpern, Scott D.
Ko, Yi-An
Matlock, Daniel D.
Mitchell, Andrea R.
Moore, Miranda A.
Morris, Alanna A.
Rao, Birju R.
Scherer, Laura D.
Speight, Candace D.
Ubel, Peter A.
Dickert, Neal W.
author_facet Thomson, Mary C.
Allen, Larry A.
Halpern, Scott D.
Ko, Yi-An
Matlock, Daniel D.
Mitchell, Andrea R.
Moore, Miranda A.
Morris, Alanna A.
Rao, Birju R.
Scherer, Laura D.
Speight, Candace D.
Ubel, Peter A.
Dickert, Neal W.
author_sort Thomson, Mary C.
collection PubMed
description Background. Presenting numeric data alone may result in patients underappreciating clinically significant benefits. Contextualizing statements to counter this may raise concern about absence of neutrality. These issues arose during construction of a decision aid for sacubitril-valsartan, a heart failure medication associated with a ∼3% absolute reduction in 2-year mortality that carries high out-of-pocket cost. A contextualizing statement framing this as a “pretty big benefit” was incorporated. The impact of statements like this within decision aids is unknown. Objective. This online Qualtrics survey sought to deepen understanding of benefit framing by testing the impact of varying contextualizing statements within a decision aid for sacubitril-valsartan. Design. Participants were randomly assigned to receive one of six abbreviated versions of a decision aid for sacubitril-valsartan that varied only by contextualizing statement (ranging from strongly neutral to strongly positive and using relative and absolute risk reductions). Participants were asked to answer questions regarding the likelihood of taking the medication at a cost of $50/month and their perception of the drug’s benefits. Results. A total of 1873 participants who were demographically similar to the heart failure population completed the survey. Fifty-four percent were willing to take sacubitril-valsartan at $50/month. Each of the five experimental contextualizing statements was compared with the baseline version; no significant differences were observed in reported likelihood of taking sacubitril-valsartan. After controlling for demographics and covariates, group assignment did not predict likelihood of taking the medication. Higher income, better self-reported health status, and younger age were associated with increased likelihood of taking sacubitril-valsartan. Limitations. This study used a hypothetical scenario and evaluated one method of delivering contextualizing statements. Conclusions. Contextualizing statements as tested within this decision aid did not affect decision making.
format Online
Article
Text
id pubmed-8529322
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85293222021-10-22 Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure Thomson, Mary C. Allen, Larry A. Halpern, Scott D. Ko, Yi-An Matlock, Daniel D. Mitchell, Andrea R. Moore, Miranda A. Morris, Alanna A. Rao, Birju R. Scherer, Laura D. Speight, Candace D. Ubel, Peter A. Dickert, Neal W. MDM Policy Pract Original Research Article Background. Presenting numeric data alone may result in patients underappreciating clinically significant benefits. Contextualizing statements to counter this may raise concern about absence of neutrality. These issues arose during construction of a decision aid for sacubitril-valsartan, a heart failure medication associated with a ∼3% absolute reduction in 2-year mortality that carries high out-of-pocket cost. A contextualizing statement framing this as a “pretty big benefit” was incorporated. The impact of statements like this within decision aids is unknown. Objective. This online Qualtrics survey sought to deepen understanding of benefit framing by testing the impact of varying contextualizing statements within a decision aid for sacubitril-valsartan. Design. Participants were randomly assigned to receive one of six abbreviated versions of a decision aid for sacubitril-valsartan that varied only by contextualizing statement (ranging from strongly neutral to strongly positive and using relative and absolute risk reductions). Participants were asked to answer questions regarding the likelihood of taking the medication at a cost of $50/month and their perception of the drug’s benefits. Results. A total of 1873 participants who were demographically similar to the heart failure population completed the survey. Fifty-four percent were willing to take sacubitril-valsartan at $50/month. Each of the five experimental contextualizing statements was compared with the baseline version; no significant differences were observed in reported likelihood of taking sacubitril-valsartan. After controlling for demographics and covariates, group assignment did not predict likelihood of taking the medication. Higher income, better self-reported health status, and younger age were associated with increased likelihood of taking sacubitril-valsartan. Limitations. This study used a hypothetical scenario and evaluated one method of delivering contextualizing statements. Conclusions. Contextualizing statements as tested within this decision aid did not affect decision making. SAGE Publications 2021-10-18 /pmc/articles/PMC8529322/ /pubmed/34693019 http://dx.doi.org/10.1177/23814683211041623 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Thomson, Mary C.
Allen, Larry A.
Halpern, Scott D.
Ko, Yi-An
Matlock, Daniel D.
Mitchell, Andrea R.
Moore, Miranda A.
Morris, Alanna A.
Rao, Birju R.
Scherer, Laura D.
Speight, Candace D.
Ubel, Peter A.
Dickert, Neal W.
Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure
title Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure
title_full Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure
title_fullStr Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure
title_full_unstemmed Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure
title_short Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure
title_sort framing benefits in decision aids: effects of varying contextualizing statements on decisions about sacubitril-valsartan for heart failure
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529322/
https://www.ncbi.nlm.nih.gov/pubmed/34693019
http://dx.doi.org/10.1177/23814683211041623
work_keys_str_mv AT thomsonmaryc framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT allenlarrya framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT halpernscottd framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT koyian framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT matlockdanield framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT mitchellandrear framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT mooremirandaa framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT morrisalannaa framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT raobirjur framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT schererlaurad framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT speightcandaced framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT ubelpetera framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure
AT dickertnealw framingbenefitsindecisionaidseffectsofvaryingcontextualizingstatementsondecisionsaboutsacubitrilvalsartanforheartfailure